NEUROMOD DISTRIBUTION LIMITED

Neuromod Distribution Limited is a global medical‑technology company dedicated to transforming the lives of people living with tinnitus. Through scientific innovation and a patient‑centred ethos, Neuromod has created Lenire – the world’s first and only FDA‑approved bimodal neuromodulation device for tinnitus treatment. Lenire’s safety and efficacy have been demonstrated in three large‑scale, peer‑reviewed clinical trials involving more than 600 patients, and the device is now available in over 130 clinics across Europe and the United States.

Beyond the device itself, Neuromod offers a comprehensive suite of services to support clinicians and patients alike. The company holds more than 136 patents in 37 countries, supplies a fully industrialised manufacturing and redundant global supply chain, and provides an all‑in‑one Partner Platform that streamlines clinic onboarding, profitability and patient‑care excellence. In addition, Neuromod delivers in‑depth clinical and commercial training, ensuring that the 200+ clinicians using Lenire feel confident and equipped to deliver best‑in‑class tinnitus care.

By marrying cutting‑edge research with practical practice enablement, Neuromod Distribution Limited is setting a new standard for tinnitus treatment, helping sufferers reclaim quiet and quality of life.